This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Guadecitabine treatment resulted in a 150% increase in SSTR2 uptake in BON-1 models.
Why it matters
Enhancing SSTR2 expression could expand treatment options for patients with neuroendocrine neoplasias who currently lack effective therapies. This research opens the door for improved outcomes in peptide receptor radionuclide therapy.
How the study worked
The study involved in vitro and in vivo experiments using neuroendocrine neoplasia models, methylation profiling of clinical samples, and safety assessments for combined treatment.
What this study cannot tell us
The study primarily focused on specific cell lines and may not fully represent all neuroendocrine neoplasias in patients.
Read the original research
Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy.
European journal of cancer (Oxford, England : 1990), 176, 110-120
Citation
Evans, Joanne S; Beaumont, Jamie; Braga, Marta; Masrour, Nahal; Mauri, Francesco; Beckley, Alice; Butt, Shamus; Karali, Christina S; Cawthorne, Chris; Archibald, Stephen; Aboagye, Eric O; Sharma, Rohini. (2022). Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy.. European journal of cancer (Oxford, England : 1990), 176, 110-120. https://doi.org/10.1016/j.ejca.2022.09.009